Oragenics Inc (OGEN): Big news SARS-CoV-2 Spike Protein Licens...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	118
Posts	12540
Boards Moderated	5
Alias Born	05/23/2007

saj

Re: None

Tuesday, 02/02/2021 8:01:02 AM

Tuesday, February 02, 2021 8:01:02 AM

Big news SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice
BUSINESS WIRE 6:00 AM ET 2/2/2021

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent OGEN News

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/27/2024 10:09:12 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:04:34 PM
Oragenics Announces Proposed Public Offering • Business Wire • 02/27/2024 09:33:00 PM
Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/13/2024 01:06:23 AM
Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:45:18 PM
Oragenics, Inc. Announces Leadership Transition • Business Wire • 02/12/2024 09:41:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:18 PM
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement • Business Wire • 02/07/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:00:23 PM
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion • Business Wire • 02/05/2024 01:00:00 PM
Oragenics Announces Termination of At-The-Market Offering Program • Business Wire • 01/23/2024 10:34:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:18:59 PM
Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 10:30:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:10:51 PM
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 01/16/2024 02:08:13 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2024 02:04:40 PM

More OGEN News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover